Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Abstract Background We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. Methods Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). The prognostic value for progression-free survival...

Full description

Bibliographic Details
Main Authors: Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean-Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie-Cécile Le Deley
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Angiosarcoma
Bevacizumab
Biomarkers
Radiation-induced angiosarcoma
Weekly paclitaxel
Online Access:http://link.springer.com/article/10.1186/s12885-018-4828-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4828-1

Similar Items